Author: <span>Asbestos / Mesothelioma News From Medical News Today</span>

Statistical model may identify patients most likely to benefit from surgery for mesothelioma

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article…

Statistical model may identify patients most likely to benefit from surgery for mesothelioma

A new statistical model may help predict which patients are most likely to receive life-extending benefits from surgical treatment for malignant pleural mesothelioma (MPM), according to an article…

Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma

PharmaMar has announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.

Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma

PharmaMar has announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.

Trabectedin shows activity in ATREUS trial in patients with sarcomatoid malignant mesothelioma

PharmaMar has announced data from a Phase 2 study in patients with sarcomatoid/biphasic malignant pleural mesothelioma showing that 41.2% (95% CI: 18.4-67.

Genelux announces promising data from two phase I trials of GL-ONC1 in head and neck cancer and mesothelioma

Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials…

Genelux announces promising data from two phase I trials of GL-ONC1 in head and neck cancer and mesothelioma

Genelux Corporation, a clinical-stage biopharmaceutical company focused on the development of vaccinia virus for oncolytic immunotherapy, today announced that data from two Phase I trials…

Investigational personalized cellular therapy tolerated well by patients

Promising results of Phase I trial show successful migration of immune cells to tumor sitesGenetically modified versions of patients’ own immune cells successfully traveled to tumors they were…